This is the authors' abstract. We don't add key points for this paper.
BACKGROUND: Cancer remains the second leading cause of death worldwide, emphasizing the urgent need for more effective therapies. One promising approach is the use of naturally occurring molecules. The short-chain fatty acid butyrate has attracted attention for its protective and anticancer properties in colorectal cancer. However, the beneficial effects of butyrate are restricted to colonocytes. To determine whether systemically available butyrate derivatives could elicit similar effects in other cell types, we investigated 4-phenylbutyrate and β-hydroxybutyrate treatment regimens in a non-colon BALB/c cell line. MATERIALS AND METHODS: The anticarcinogenic potential of butyrate derivatives was evaluated using the BALB/c tumor therapy model, which simulates the early stages of malignant cell transformation. Mechanistic effects were investigated through immunoblotting and flow cytometry. Furthermore, butyrate and 4-phenylbutyrate resulted in reduced caspase-3 activation, while simultaneously increasing the number of apoptotic cells. β-hydroxybutyrate did not show measurable effects in the parameters investigated. CONCLUSION: In summary, this study provides a new comparative insight into both anticancer effects and the underlying mechanisms of action of the three butyrate derivatives in a non-colon cell model. Our findings indicate that 4-phenylbutyrate represents the more promising derivative in the BALB/c tumor therapy model.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Katsika et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: